Opsens downgraded to Market Perform from Outperform at Raymond James

Raymond James downgraded Opsens (OPSSF) to Market Perform from Outperform with a price target of C$2.90, down from C$3.50, after the company signed an agreement to be acquired by Haemonetics (HAE) for C$2.90 per share in cash, valuing Opsens at C$345M. Raymond James does not view this deal as a great outcome for Opsens’ shareholders, and predicts a non-zero probability of an over-the-top bid from a better- suited party willing to pay a fairer price for the cath lab products, the analyst says in a research note.